Article Versions Notes

Szafraniec-Szczęsny J, Antosik-Rogóż A, Kurek M, Gawlak K, Górska A, Peralta S, Knapik-Kowalczuk J, Kramarczyk D, Paluch M, Jachowicz R. How Does the Addition of Kollidon^®VA64 Inhibit the Recrystallization and Improve Ezetimibe Dissolution from Amorphous Solid Dispersions? Pharmaceutics. 2021; 13(2):147. https://doi.org/10.3390/pharmaceutics13020147

Szafraniec-Szczęsny, Joanna, Agata Antosik-Rogóż, Mateusz Kurek, Karolina Gawlak, Anna Górska, Sebastian Peralta, Justyna Knapik-Kowalczuk, Daniel Kramarczyk, Marian Paluch, and Renata Jachowicz. 2021. "How Does the Addition of Kollidon^®VA64 Inhibit the Recrystallization and Improve Ezetimibe Dissolution from Amorphous Solid Dispersions?" Pharmaceutics 13, no. 2: 147. https://doi.org/10.3390/pharmaceutics13020147

Szafraniec-Szczęsny, J., Antosik-Rogóż, A., Kurek, M., Gawlak, K., Górska, A., Peralta, S., Knapik-Kowalczuk, J., Kramarczyk, D., Paluch, M., & Jachowicz, R. (2021). How Does the Addition of Kollidon^®VA64 Inhibit the Recrystallization and Improve Ezetimibe Dissolution from Amorphous Solid Dispersions? Pharmaceutics, 13(2), 147. https://doi.org/10.3390/pharmaceutics13020147